The observational pilot study at the Churchill Hospital, funded by Oxford Respiratory Trials Unit, will assess the feasibility and efficacy of thoracic ultrasound (TUS) assessment in patients undergoing talc pleurodesis via intercostal chest drain (ICD) for recurrent symptomatic malignant pleural effusions (MPE). Participants will undergo TUS pre and post pleurodesis on up to four occasions. We hypothesise that a TUS scoring system will be able to predict short and long-term pleurodesis success earlier than current conventional medical practice allows. This study may ultimately allow the proposal of a treatment algorithm to manage patients with MPE in a more efficient manner.
Study Type
OBSERVATIONAL
Enrollment
18
Oxford Respiratory Trials Unit, Churchill Hospital
Oxford, United Kingdom
Clinico-radiological confirmation of pleurodesis success post pleurodesis.
Pleurodesis success confirmed as no radiographic and/or ultrasonographic evidence of significant pleural fluid recurrence; and/or no clinical need for further pleural intervention for symptomatic relief.
Time frame: 1 month
Clinico-radiological confirmation of pleurodesis success post pleurodesis.
Pleurodesis success confirmed as no radiographic and/or ultrasonographic evidence of significant pleural fluid recurrence; and/or no clinical need for further pleural intervention for symptomatic relief.
Time frame: 3 months
Difference (in days) between hypothetical discharge date based on thoracic ultrasound findings and actual discharge date based on standard clinical care.
Time frame: Through study completion, an average of 3 months.
Patient satisfaction with thoracic ultrasound as measured using a Likert-type scale
Time frame: Through study completion, an average of 3 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.